Christie research shows acupuncture helps chemo patients

Date published: 31 December 2019

Pioneering research by The Christie NHS Foundation Trust in Manchester has found that acupuncture can help more than half of patients who suffer from neuropathy, a debilitating numbness, which can be caused by chemotherapy. 

Believed to be the largest study of its kind ever undertaken, the aim was to discover if acupuncture, added to standard of care medication for patients experiencing severe chemo-inducted peripheral neuropathy, can significantly improve the condition for many. 

The trial involved 120 patients over three years at two of the cancer centre’s sites in Withington and Oldham in Greater Manchester.  

Half the group were offered weekly hour-long acupuncture sessions over a 10 week period. Patients described then graded their own worst symptoms at the beginning and end of their treatment.

As a result of the sessions, 68% found their dexterity and mobility improved.

Neuropathy causes multiple debilitating symptoms including incapacitating numbness, excruciating pain and severe tingling or ‘pins and needles’, which can make driving, walking and performing everyday tasks such as washing, dressing, cooking and shopping impossible.  

Professor Andrew Wardley, consultant medical oncologist at The Christie and chief investigator for the ACUFOCIN trial, said, “We believed acupuncture could help patients with chemo-induced peripheral neuropathy but there was no real evidence of this.

A study of this size had not been undertaken before, as far as we were aware, and so we decided to try and prove it for ourselves. We hope this trial will lead to a new standard of care for treating this condition, improving the lives of millions of patients.” 

Dr Jacqui Stringer, lead for complementary health and wellbeing at The Christie, commenting on the trial, said: “The results were phenomenal and validated earlier clinical data.

The patients eligible to enter the study were all experiencing serious problems with their motor function as a result of chemotherapy, some for several years.

We know neuropathy is more prevalent in patients treated with certain chemotherapy drugs such as ’Taxanes’. It is hoped this trial acts as a springboard to a larger, multi-centre study to further explore how we can best help patients suffering from this debilitating condition during and after treatment. It will help so many people who have finished treatment but still aren’t able to get back to a normal life.”

The Christie NHS Foundation Trust was the first specialist trust to be rated as ‘Outstanding’ twice (in 2016 and 2018) by the health regulator the Care Quality Commission (CQC). 

Do you have a story for us? Want to tell us about something going on in and around Oldham? Let us know by emailing , calling our Oldham-based newsroom on 0161 633 2121 , tweeting us @oldhamchronicle or messaging us through our Facebook page. All contact will be treated in confidence.